The MedTech startup based in Zurich has secured more than CHF 2.3 million in seed financing. Among the family offices and private investors are the GF Group Holding AG and AVANTECA Partners AG. The funds will allow Oncobit to expand its team and launch its cancer diagnostics and monitoring products on the European market, getting one step closer to enabling more personalized care for patients suffering from cancer.
In the course of the investment round, a new Board of Directors has been elected. Previous board members and co-founders Stefan Bleuler and Tomas Hruz were joined by Christian Schilling, former senior pharma executive and managing partner of AVANTECA Partners AG, and diagnostic expert Daniel Schöner as an independent board member. The board will be led by the newly elected President of the Board, Ruedi Gygax, who, as former Managing Director at the Novartis Venture Fund contributes essential experience in building and growing HealthCare Startups.
CEO Claudia Scheckel, on closing the seed financing round, says “I couldn’t be more thrilled about our new investors and board members. Every one of them shares our vision of empowering personalized cancer care and brings in complementary industry experience to put Oncobit at the forefront of precision medicine. I am very much looking forward to taking Oncobit to the next level together.”
